MedTrace Logo

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome

NCT00768820 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-03-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Conditions

  • Velocardiofacial Syndrome
  • Williams Syndrome
  • Fragile X Syndrome

Interventions

DRUG

methylphenidate, fluoxetin, risperidone

first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate

Sponsors & Collaborators

  • The Chaim Sheba Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768820 on ClinicalTrials.gov